GRPr and PSMA expression were compared on primary prostate cancer samples (Schollhammer et al. 2019; Touijer et al. 2019) as well as patients (Baratto et al. 2020) providing evidence that the biodstribution for the two radioligands were distinct. This evidence concerns the gene FOLH1 and prostate carcinoma.